Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Long‐term outcomes after randomization to buprenorphine/naloxone versus methadone in a multi‐site trial
Yih‐Ing Hser, Elizabeth Evans, David Huang, et al.
Addiction (2015) Vol. 111, Iss. 4, pp. 695-705
Open Access | Times Cited: 192

Showing 1-25 of 192 citing articles:

Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder
Sarah E. Wakeman, Marc R. Larochelle, Omid Ameli, et al.
JAMA Network Open (2020) Vol. 3, Iss. 2, pp. e1920622-e1920622
Open Access | Times Cited: 709
Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial
Joshua D. Lee, Edward V. Nunes, Patricia Novo, et al.
The Lancet (2017) Vol. 391, Iss. 10118, pp. 309-318
Open Access | Times Cited: 610
Opioid use disorder
John Strang, Nora D. Volkow, Louisa Degenhardt, et al.
Nature Reviews Disease Primers (2020) Vol. 6, Iss. 1
Closed Access | Times Cited: 440
Association of Racial/Ethnic Segregation With Treatment Capacity for Opioid Use Disorder in Counties in the United States
William C. Goedel, Aaron Shapiro, Magdalena Cerdá, et al.
JAMA Network Open (2020) Vol. 3, Iss. 4, pp. e203711-e203711
Open Access | Times Cited: 240
Medication Treatment of Opioid Use Disorder
James Bell, John Strang
Biological Psychiatry (2019) Vol. 87, Iss. 1, pp. 82-88
Open Access | Times Cited: 231
Addiction consultation services – Linking hospitalized patients to outpatient addiction treatment
Paul Trowbridge, Zoe Weinstein, Todd Kerensky, et al.
Journal of Substance Abuse Treatment (2017) Vol. 79, pp. 1-5
Open Access | Times Cited: 200
The Role of Behavioral Interventions in Buprenorphine Maintenance Treatment: A Review
Kathleen M. Carroll, Roger D. Weiss
American Journal of Psychiatry (2016) Vol. 174, Iss. 8, pp. 738-747
Open Access | Times Cited: 195
Weekly and Monthly Subcutaneous Buprenorphine Depot Formulations vs Daily Sublingual Buprenorphine With Naloxone for Treatment of Opioid Use Disorder
Michelle R. Lofwall, Sharon Walsh, Edward V. Nunes, et al.
JAMA Internal Medicine (2018) Vol. 178, Iss. 6, pp. 764-764
Open Access | Times Cited: 186
Long-term retention in Office Based Opioid Treatment with buprenorphine
Zoe Weinstein, Hyun-Joong Kim, Debbie M. Cheng, et al.
Journal of Substance Abuse Treatment (2016) Vol. 74, pp. 65-70
Open Access | Times Cited: 180
Buprenorphine Treatment for Opioid Use Disorder: An Overview
Matisyahu Shulman, Jonathan Wai, Edward V. Nunes
CNS Drugs (2019) Vol. 33, Iss. 6, pp. 567-580
Open Access | Times Cited: 145
Buprenorphine versus methadone for the treatment of opioid dependence: a systematic review and meta-analysis of randomised and observational studies
Louisa Degenhardt, Brodie Clark, Georgina Macpherson, et al.
The Lancet Psychiatry (2023) Vol. 10, Iss. 6, pp. 386-402
Closed Access | Times Cited: 52
Medication-Assisted Treatment for Opioid-Use Disorder
Tyler Oesterle, Nuria J. Thusius, Teresa A. Rummans, et al.
Mayo Clinic Proceedings (2019) Vol. 94, Iss. 10, pp. 2072-2086
Open Access | Times Cited: 120
Relapse to opioid use disorder after inpatient treatment: Protective effect of injection naltrexone
Edward V. Nunes, Michael Gordon, Peter D. Friedmann, et al.
Journal of Substance Abuse Treatment (2017) Vol. 85, pp. 49-55
Open Access | Times Cited: 106
The impact of buprenorphine and methadone on mortality: a primary care cohort study in the United Kingdom
Matthew Hickman, Colin Steer, Kate Tilling, et al.
Addiction (2018) Vol. 113, Iss. 8, pp. 1461-1476
Open Access | Times Cited: 101
Access to Office-Based Buprenorphine Treatment in Areas With High Rates of Opioid-Related Mortality
Tamara Beetham, Brendan Saloner, Sarah E. Wakeman, et al.
Annals of Internal Medicine (2019) Vol. 171, Iss. 1, pp. 1-1
Open Access | Times Cited: 91
Unintentional drug overdose: Is more frequent use of non-prescribed buprenorphine associated with lower risk of overdose?
Robert G. Carlson, Raminta Daniulaityte, Sydney M. Silverstein, et al.
International Journal of Drug Policy (2020) Vol. 79, pp. 102722-102722
Open Access | Times Cited: 82
Opioid use disorder treatment for people experiencing homelessness: A scoping review
Matthew F. McLaughlin, Rick Li, Nicolás Domínguez Carrero, et al.
Drug and Alcohol Dependence (2021) Vol. 224, pp. 108717-108717
Open Access | Times Cited: 55
Tobacco, illicit drugs use and risk of cardiovascular disease in patients living with HIV
Sergio Raposeiras‐Roubín, Emad Abu-Assi, Andrés Íñiguez
Current Opinion in HIV and AIDS (2017) Vol. 12, Iss. 6, pp. 523-527
Closed Access | Times Cited: 67
Can neuroimaging help combat the opioid epidemic? A systematic review of clinical and pharmacological challenge fMRI studies with recommendations for future research
Hestia Moningka, Sarah Lichenstein, Patrick D. Worhunsky, et al.
Neuropsychopharmacology (2018) Vol. 44, Iss. 2, pp. 259-273
Open Access | Times Cited: 67
The association of psychedelic use and opioid use disorders among illicit users in the United States
Vincent D. Pisano, Nathaniel P Putnam, Hannah M. Kramer, et al.
Journal of Psychopharmacology (2017) Vol. 31, Iss. 5, pp. 606-613
Closed Access | Times Cited: 63
Correlates of Long-Term Opioid Abstinence After Randomization to Methadone Versus Buprenorphine/Naloxone in a Multi-Site Trial
Yuhui Zhu, Elizabeth Evans, Larissa J. Mooney, et al.
Journal of Neuroimmune Pharmacology (2018) Vol. 13, Iss. 4, pp. 488-497
Open Access | Times Cited: 63
Comparison between buprenorphine provider availability and opioid deaths among US counties
Christopher W. Jones, Zachary Christman, Christopher M. Smith, et al.
Journal of Substance Abuse Treatment (2018) Vol. 93, pp. 19-25
Closed Access | Times Cited: 60
Technology and Mental Health: State of the Art for Assessment and Treatment
Philip D. Harvey, Colin A. Depp, Albert Rizzo, et al.
American Journal of Psychiatry (2022) Vol. 179, Iss. 12, pp. 897-914
Closed Access | Times Cited: 33
Opioid agonist treatment for people who are dependent on pharmaceutical opioids
Suzanne Nielsen, Wai Chung Tse, Briony Larance
Cochrane library (2022) Vol. 2022, Iss. 9
Open Access | Times Cited: 30
Examining how support persons’ buprenorphine attitudes and their communication about substance use impacts patient well-being
Jasmin Choi, Lane F. Burgette, Katherine Nameth, et al.
The American Journal of Drug and Alcohol Abuse (2025), pp. 1-11
Closed Access
Page 1 - Next Page

Scroll to top